Bavencio

Active Ingredient(s): Avelumab
FDA Approved: * March 23, 2017
Pharm Company: * EMD SERONO INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Bavencio Overview

Avelumab (MSB0010718C) is a fully human monoclonal PD-L1 antibody of isotype IgG1, currently in development by Merck KGaA, Darmstadt, Germany & Pfizer for use in immunotherapy, especially for treatment of Non-small-cell lung carcinoma (NSCLC) .[1] Approved by US FDA in 2017 for Merkel cell carcinoma. Contents 1 Mechanism of action 2 Clinical trials 3 Approvals and indications 3.1 Merkel-cell carcinoma 4 See also 5 References Mechanism of action Avelumab binds to the PD liga...

Read more Bavencio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Avelumab

Recent Bavencio Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Avelumab
  • Injection: 20mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Bavencio: (1 result)

Sorted by National Drug Code
  • 44087-3535 Bavencio 20 mg/ml Intravenous Injection, Solution, Concentrate by Emd Serono, Inc.

Other drugs which contain Avelumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 23 June 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.